4.7 Article

Clinical and Socioeconomic Burden of Respiratory Syncytial Virus Infection in Children

期刊

JOURNAL OF INFECTIOUS DISEASES
卷 215, 期 1, 页码 17-23

出版社

OXFORD UNIV PRESS INC
DOI: 10.1093/infdis/jiw475

关键词

burden of illness; children; respiratory syncytial virus; vaccines; antivirals

资金

  1. Novavax
  2. Wyeth
  3. GlaxoSmithKline
  4. Academy of Finland
  5. European Scientific Working Group on Influenza
  6. Foundation for Pediatric Research in Finland
  7. Jenny and Antti Wihuri Foundation, Finland

向作者/读者索取更多资源

Background. Vaccines and antivirals against respiratory syncytial virus (RSV) are being developed, but there are scarce data on the full impact of RSV infection on outpatient children. Methods. We analyzed the burden of RSV illness in a prospective cohort study of children aged <= 13 years during 2 consecutive respiratory seasons in Turku, Finland (2231 child-seasons of follow-up). We examined the children and obtained nasal swabs for the detection of RSV during each respiratory illness. The parents filled out daily symptom diaries throughout the study. Results. Of 6001 medically attended respiratory infections, 302 (5%) were caused by RSV. Per 1000 children, the average annual RSV infection incidence rates among children aged < 3, 3-6, and 7-13 years were 275, 117, and 46 cases, respectively. In children aged < 3 years, acute otitis media developed in 58%, and 66% of children in this age group received antibiotics. The mean duration of RSV illness was longest (13.0 days) and the rate of parental work absenteeism was highest (136 days per 100 children with RSV illness) in children aged < 3 years. Conclusions. The burden of RSV is particularly great among outpatient children aged < 3 years. Young children are an important target group for the development of RSV vaccines and antivirals.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.7
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据